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The interaction of bovine seminalplasmin and rifampicin with E.coli RNA polymerase was studied using 
fluorescence spectroscopy. Both seminalplasmin and rifampicin are known to be the inhibitors for the initia- 
tion of RNA synthesis in E.coli. Rifampicin quenced the intrinsic fluorescence of RNA polymerase and 
seminalplasmin when excited at 280 nm. However, excess of seminalplasmin reversed the quenching of RNA 
polymerase fluorescence by rifampicin. Upon addition of rifampicin to the seminalplasmin-RNA polymer- 
ase complex, no change in fluorescence spectrum was observed. It appeared that although rifampicin could 
form complexes with RNA polymerase and seminalplasmin alone, no binding domain was available for ri- 
fampicin in the RNA polymerase-seminalplasmin complex. These observations are discussed in the light 
of the ‘initiation site’ of E.coli RNA polymerase. 
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1. INTRODUCTION 
Seminalplasmin, a 6-kDa protein from bovine 
seminal plasma, has been shown to be an inhibitor 
of transcription in Escherichia coli and it does so 
in vitro by binding strongly to RNA polymerase 
[1,2]. It has been shown further that seminal- 
plasmin inhibits the formation of the first phos- 
phodiester bond or the initiation of RNA syn- 
thesis, at least in the case of certain promoters of 
T, DNA [2]. 
It is now well established that, unlike many 
other compounds that interfere with transcription 
[3], the antibiotic rifampicin, a specific inhibitor of 
bacterial RNA polymerase acts by direct interac- 
tion with the enzyme [4], forming a remarkably 
stable, stoichiometric complex. Probably, rifam- 
picin inhibits RNA synthesis at the level of initia- 
tion [5,6]. In the light of these observations, we 
thought it of interest to study the competitive bind- 
ing of seminalplasmin and rifampicin with E. coli 
RNA polymerase under non-transcribing condi- 
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tions, i.e., in the absence of both template and 
substrate. 
We attempted to study the interaction of seminal- 
plasmin and rifampicin with E. coli RNA poly- 
merase by using fluorescence spectroscopy. Rifam- 
picin quenches the intrinsic fluorescence of RNA 
polymerase through energy transfer [7]; the known 
amino acid sequence of seminalplasmin shows that 
it has a single tryptophan making the protein in- 
trinsically fluorescent [8]. 
2. EXPERIMENTAL PROCEDURE 
E. coli RNA polymerase was purified as de- 
scribed before [9] from 250 g cells (MRE 600, 
RNase l-) grown up to the log phase in a 40-l 
fermentor. The 5OO-kDa enzyme with subunit 
composition &fl’c was found to be more than 
90% pure on SDS-polyacrylamide gel elec- 
trophoresis (not shown) and had a specific activity 
of 1200 units/ mg. Seminalplasmin was purified 
following the standard procedure developed in this 
laboratory [ 11. Rifampicin bought from Sigma was 
used without further purification. All the 
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nucleoside triphosphates and other reagents used 
were of the purest grade available. [3H]UTP used 
for assaying RNA polymerase was obtained from 
New England Nuclear. Uncorrected fluorescence 
emission spectra were recorded on a 650-10s 
Hitachi spectrofluorimeter. The concentrations of 
the enzyme, seminalplasmin and rifampicin were 
fixed spectrophotometrically, using the values 
A&‘lY”“t = 0.62 for RNA polymerase, _4&$g’m1 =
1.07 for seminalplasmin and the molar extinction 
coefficient of 28000 for rifampicin at 334 nm. 
3. RESULTS 
All the fluorescence experiments were per- 
formed such that the total absorbance at the ex- 
citation wavelength was always less than 0.1 so as 
o- 
O- 
I 
I O- 
30 
I I I 1 I I I 0 
0 310 320 330 340 350 360 370 380 
Wavelength (nm) 
Fig.1. Fluorescence emission spectra of E. coli RNA 
polymerase in the presence of rifampicin and bovine 
seminalplasmin at 24°C (excitation wavelength 280 nm). 
a, RNA polymerase (2.6x lo-* M); b, (a) + rifampicin 
(3 x 1O-8 M); c, seminalplasmin (2.8 x lo-’ M); d, RNA 
polymerase (2.6 x 10e8 M) + seminalplasmin (2.8 x lo-’ 
Fig.2. Fluorescence emission spectra of E. coli RNA 
polymerase, and bovine seminalplasmin in the presence 
of rifampicin, at 24°C (excitation wavelength, 280 nm). 
a, RNA polymerase (2.6x 10e8 M) + rifampicin 
(3 x 10e8 M); b, (a) + seminalplasmin (2.8 x lo-’ M); c, 
seminalplasmin (2.8~ lo-’ M); d, (c) + rifampicin 
(3 x 1O-8 M); the inset shows the variation of the 
fluorescence intensity (I) at 340 nm with different molar 
ratios of seminalplasmin (SPLN) to the RNA 
M); e, (d) + rifampicin (3 x 10m8 M). polymerase (RPase) - rifampicin (Rif) complex. 
to avoid the inner filter effect. The measurements 
were carried out at 25°C in a buffer containing 0.1 
M KC1 and 10 mM Tris-HCl (pH 8). Fig.1 shows 
the typical fluorescence mission spectrum of RNA 
polymerase when excited at 280 nm. Upon addi- 
tion of an equimolar quantity of rifampicin, the 
340 nm emission band of RNA polymerase was 
quenched due to complexation, as expected. Fig. 1 
also shows the emission spectrum of seminal- 
plasmin and that of RNA polymerase with seminal- 
plasmin when the latter is in IO-fold molar excess, 
the excitation being at 280 nm. It is seen that the 
emission spectrum is simply additive of the con- 
tributions of the constituents. Interestingly, it was 
observed that the addition of rifampicin to this 
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mixture of seminalplasmin and RNA polymerase 
caused little quenching of the 340 nm band (fig. 
le). This leads us to infer that rifampicin, which 
otherwise forms a strong complex with RNA poly- 
merase, may not be able to bind to the RNA poly- 
merase-seminalplasmin complex. To substantiate 
this inference, the effect of the addition of seminal- 
plasmin to the preformed RNA polymerase rifam- 
picin complex was studied (vide, fig.2). The con- 
centration of seminalplasmin was varied up to a 
IO-fold molar excess to that of RNA polymerase 
alone (inset, fig.2). At lower molar ratios of 
seminalplasmin:(RNA polymerase-rifampicin), the 
emission spectra were the summation of that of 
enzyme-rifampicin complex and that of seminal- 
plasmin. However, at IO-fold molar excess of 
seminalplasmin, the quenching effect of rifampicin 
on RNA polymerase was abolished, generating the 
emission spectrum (fig.2b) as that shown previous- 
ly for the seminalplasmin-RNA polymerase com- 
plex (see fig.ld). However, it was observed that 
rifampicin is able to quench the emission band of 
seminalplasmin alone when excited at 280 nm 
(vide, fig.2d). This observation suggests that a 
direct interaction exists between free seminal- 
plasmin and the antibiotic rifampicin. 
4. DISCUSSION 
The reversible nature of rifampicin binding to 
RNA polymerase has been established earlier 
through fluorescence titration [4]. Both the associ- 
ation and dissociation reaction rates are biphasic, 
and MgCl2 and DNA influence the fast or slow 
phases in different proportions. It has also been 
postulated by Bahr et al. [4] that there exist two 
putative structural states of the enzyme for binding 
to the antibiotic. Our measurements were done at 
equilibrium and thus represent a gross change of 
the enzyme upon binding to rifampicin. The emis- 
sion spectrum of seminalplasmin, typical of that of 
tryptophan fluorescence, is quite weak in the con- 
centration range we have studied. However, on ad- 
dition of the seminalplasmin to RNA polymerase, 
the emission band was found to be additive, in- 
dicating thereby that any interaction between these 
two species could not be followed by fluorescence 
spectroscopy. 
Out of the two zinc atoms that are tightly bound 
to E. coli RNA polymerase, the one in the ,&- 
subunit is involved in RNA chain initiation and 
directly participates in the reaction [ 111. Moreover, 
it is the P-subunit of RNA polymerase which car- 
ries the binding site for rifampicin [12]. It is thus 
tempting to speculate that this zinc-containing 
region of the P-subunit is mainly responsible for 
the binding of both seminalplasmin and rifam- 
picin. It should be mentioned here that seminal- 
plasmin is also an inhibitor for reverse transcrip- 
tase which again is a Zn-containing enzyme [13]. 
Whether seminalplasmin has any special affinity 
towards Zn-containing sites in proteins is currently 
being studied in our laboratory. 
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